| 1 |
34764434 | BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. | 2022 Apr |
1 |
| 2 |
34732441 | Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma. | 2021 Nov |
1 |
| 3 |
32606309 | Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2. | 2020 Jun 30 |
1 |
| 4 |
30850381 | Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. | 2019 May 2 |
1 |
| 5 |
31462891 | Haploinsufficiency of NR3C1 drives glucocorticoid resistance in adult acute lymphoblastic leukemia cells by down-regulating the mitochondrial apoptosis axis, and is sensitive to Bcl-2 blockage. | 2019 |
1 |
| 6 |
29199519 | Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma. | 2018 Aug |
1 |
| 7 |
28154089 | Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. | 2017 May |
1 |
| 8 |
24088574 | The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. | 2013 Oct 2 |
1 |
| 9 |
22213394 | Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. | 2012 Sep 1 |
1 |
| 10 |
22851565 | Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. | 2012 Oct 1 |
1 |
| 11 |
12469194 | Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. | 2003 Jan |
4 |
| 12 |
10930993 | Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. | 2000 Jul |
2 |